Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin B3, also known as niacin or nicotinamide, has some scientific evidence supporting its use in the management of psoriasis, though the evidence is limited and not robust. Topical formulations of nicotinamide have been investigated for their anti-inflammatory properties, which are relevant because psoriasis is an inflammatory skin disease. Some small clinical studies and case reports suggest that topical nicotinamide may help reduce the severity of psoriatic lesions by inhibiting the release of pro-inflammatory cytokines and improving skin barrier function. Additionally, niacin derivatives have been shown in laboratory settings to influence keratinocyte proliferation and differentiation, processes that are dysregulated in psoriasis.

However, the overall quality and quantity of clinical trials specifically examining Vitamin B3 for psoriasis is low, and it is not widely recognized as a standard treatment in dermatological guidelines. Most evidence comes from small-scale studies or adjunctive use rather than as a primary therapy. Oral niacin is not commonly used for psoriasis, and its side effects (such as flushing and liver toxicity at high doses) limit its systemic use. In summary, while there is some scientific rationale and preliminary clinical evidence for topical Vitamin B3 in psoriasis, more large-scale and rigorous trials are needed to firmly establish its efficacy and safety.

More about Vitamin B3
More about Psoriasis

Other ingredients used for Psoriasis

Other health conditions supported by Vitamin B3

Products containing Vitamin B3